Европейски съюз - испански - EMA (European Medicines Agency)

sanofi winthrop industrie - alirocumab - dislipidemias - agentes modificadores de lípidos - hipercolesterolemia primaria y mixta dyslipidaemiapraluent está indicado en adultos con hipercolesterolemia primaria (heterocigota familiar y no familiar) o dislipemia mixta, como un complemento de la dieta:en combinación con una estatina o de estatinas con otros hipolipemiantes terapias en pacientes incapaces de alcanzar metas de ldl-c con la dosis máxima tolerada de una estatina o,solos o en combinación con otros hipolipemiantes terapias en los pacientes que son las estatinas intolerante, o que una estatina está contraindicada. establecido enfermedad cardiovascular aterosclerótica praluent está indicado en adultos con lo establecido por enfermedad cardiovascular aterosclerótica para reducir el riesgo cardiovascular mediante la reducción de niveles de ldl-c, como adyuvante a la corrección de otros factores de riesgo:en combinación con la dosis máxima tolerada de una estatina con o sin otros reductores de lípidos terapias o,solos o en combinación con otros hipolipemiantes terapias en los pacientes que son las estatinas intolerante, o que una estatina está contraindicada. para que los resultados del estudio con respecto a los efectos sobre el ldl-c, eventos cardiovasculares y de las poblaciones estudiadas, consulte la sección 5.

Европейски съюз - испански - EMA (European Medicines Agency)

sanofi winthrop industrie - la insulina glargina, lixisenatide - diabetes mellitus, tipo 2 - drogas usadas en diabetes - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Европейски съюз - испански - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - neoplasias colorrectales - agentes antineoplásicos - tratamiento del cáncer colorrectal metastásico (mcrc).

Европейски съюз - испански - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - artritis, reumatoide - inmunosupresores - kevzara en combinación con metotrexato (mtx) está indicado para el tratamiento de moderada a gravemente activa la artritis reumatoide (ar) en pacientes adultos que han respondido inadecuadamente a, o que son intolerantes a uno o más la enfermedad anti reumática fármacos (farme). kevzara puede administrarse en monoterapia en caso de intolerancia al mtx o cuando el tratamiento con mtx es inapropiado.

Европейски съюз - испански - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agentes para la dermatitis, excluidos los corticosteroides - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Европейски съюз - испански - EMA (European Medicines Agency)

sanofi winthrop industrie - insulina lispro - diabetes mellitus - drogas usadas en diabetes - para el tratamiento de adultos y niños con diabetes mellitus que requieren insulina para el mantenimiento de la homeostasis normal de glucosa. insulin lispro sanofi también está indicado para la estabilización inicial de la diabetes mellitus.

Куба - испански - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

sanofi winthrop industrie, ambares, francia. - clopidogrel - comprimido recubierto - 75 mg

Куба - испански - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

sanofi winthrop industrie, francia - comprimido recubierto

Европейски съюз - испански - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mieloma múltiple - agentes antineoplásicos - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Европейски съюз - испански - EMA (European Medicines Agency)

sanofi winthrop industrie - insulina aspart - diabetes mellitus - drogas usadas en diabetes - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.